Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Chief Accounting Officer | November 16, 2020 | November 19, 2020 |
| ChemoCentryx, Inc.CCXI · Entity 122928 | SVP, Finance & Acctg Officer | June 07, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date November 16, 2020 · Filed November 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,586 |
Ending reported balance
After 2020-11-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-11-16 · Exercise / conversion · Acquired 5,493 · Balance 6,486 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2020-11-16 · Tax withholding · Disposed 1,900 · Balance 4,586 F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 5,493 shares of Common Stock underlying the Reporting Person's RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,586 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Exercise / conversion · Disposed 399 · Balance 5,586 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 15,282 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Exercise / conversion · Disposed 5,094 · Balance 15,282 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: The RSUs vested as to 25% of the units on November 16, 2020 and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service with the Issuer or any of its subsidiaries through each such vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 5,493 shares of Common Stock underlying the Reporting Person's RSUs.
F3: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
F4: The RSUs vested as to 25% of the units on November 16, 2020 and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service with the Issuer or any of its subsidiaries through each such vesting date, and have no expiration date.
ChemoCentryx, Inc.
Report date June 07, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.19 · Expires 2032-06-07 | Direct | 65,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 65,000 · Balance 65,000 F2: Not applicable. F1: The option was granted on June 7, 2022, and 25% of the total number of shares of common stock subject to the option vests on June 6, 2023, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 7, 2022, and 25% of the total number of shares of common stock subject to the option vests on June 6, 2023, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2022 Filed Jun 8, 2022 18:33 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $25.19 | Not disclosed |
DisclosureSEC source: 0001209191-22-035196 · doc4.xml · derivative · entry 1 YAU YI CHING · CIK 0001790097 · SVP, Finance & Acctg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-07 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on June 7, 2022, and 25% of the total number of shares of common stock subject to the option vests on June 6, 2023, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:44 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 5,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031586 · doc4.xml · derivative · entry 4 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,282 Underlying: Common Stock · 5,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested as to 25% of the units on November 16, 2020 and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service with the Issuer or any of its subsidiaries through each such vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vested as to 25% of the units on November 16, 2020 and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service with the Issuer or any of its subsidiaries through each such vesting date, and have no expiration date. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:44 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 399 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031586 · doc4.xml · derivative · entry 3 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,586 Underlying: Common Stock · 399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F3 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:44 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,900 | $44.33 | $84,227.00 |
DisclosureSEC source: 0000899243-20-031586 · doc4.xml · nonDerivative · entry 2 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,586 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 5,493 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:44 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 5,493 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031586 · doc4.xml · nonDerivative · entry 1 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 22:58 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 398 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022785 · doc4.xml · derivative · entry 3 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,985 Underlying: Common Stock · 398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F4 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 22:58 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 138 | $28.53 | $3,937.14 |
DisclosureSEC source: 0000899243-20-022785 · doc4.xml · nonDerivative · entry 2 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 398 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 22:58 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022785 · doc4.xml · nonDerivative · entry 1 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| June 03, 2020 Filed Jun 6, 2020 00:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 6,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015541 · doc4.xml · derivative · entry 2 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,383 Underlying: Common Stock · 6,383 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. F3 · derivative.expiration_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| June 03, 2020 Filed Jun 6, 2020 00:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 45,931 | $0.00 Strike: $28.86 | $0.00 |
DisclosureSEC source: 0000899243-20-015541 · doc4.xml · derivative · entry 1 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,931 Underlying: Common Stock · 45,931 shares Expires 2030-06-02 F1 · derivative.exercise_date: The Option will vest over approximately four years. 1/48th of the shares of Common Stock underlying the Option will vest on a monthly basis after June 3, 2020 (the "Vesting Commencement Date"), such that all of the shares underlying the Option will be vested on the date four (4) years after the Vesting Commencement Date, subject to the Reporting Person's continued Service Relationship (as defined in the Plan) with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:07 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 55,652 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029357 · doc4.xml · derivative · entry 1 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,652 Underlying: Common Stock · 55,652 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. F2 · derivative.exercise_date: The units shall vest as to 25% of the units on February 16, 2021, and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: The units shall vest as to 25% of the units on February 16, 2021, and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| November 13, 2019 Filed Nov 16, 2019 00:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 20,376 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-027431 · doc4.xml · derivative · entry 2 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,376 Underlying: Common Stock · 20,376 shares Expires not disclosed F2 · derivative.exercise_price: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. F3 · derivative.exercise_date: The units shall vest as to 25% of the units on November 16, 2020, and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 16, 2019 00:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 78,148 | $0.00 Strike: $26.28 | $0.00 |
DisclosureSEC source: 0000899243-19-027431 · doc4.xml · derivative · entry 1 YAU YI CHING · CIK 0001790097 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,148 Underlying: Common Stock · 78,148 shares Expires 2029-11-12 F1 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares on October 7, 2020, and as to 1/48th of the shares each month thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.